[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 996
6. Wu H, Huang Q, Wang ZY, Cao RP, Zhang ZH: [Surgery of jugular foramen region tumors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Sep;41(9):665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mastoid and neck approach, the infratemporal fossa approach with and without rerouting the facial nerve, the combined transcochlear and infratemporal fossa approach were respectively used according to the tumor type, size, auditory, facial and lower cranial nerve functions.
  • RESULTS: In this series of 32 patients, 13 were paragangliomas, 10 schwannomas,2 meningiomas, 2 giant cell tumors, 1 chondrosarcoma, 1 mucochondrosarcoma, 1 adenoid cystic carcinoma, 1 rhabdomyosarcoma and 1 case cholesterol Granuloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111806.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduction and/or absence of E-cadherin was only observed in pleomorphic adenoma at the peripheral cells of the duct-like or island structures, or in the cells exhibiting plasmacytoid or stromal differentiation.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenolymphoma / chemistry. Adenoma / chemistry. Adenoma, Pleomorphic / chemistry. Humans. Immunohistochemistry / methods. Salivary Gland Diseases / metabolism. Salivary Glands / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


8. Gaissert HA, Grillo HC, Shadmehr BM, Wright CD, Gokhale M, Wain JC, Mathisen DJ: Laryngotracheoplastic resection for primary tumors of the proximal airway. J Thorac Cardiovasc Surg; 2005 May;129(5):1006-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-five patients aged 15 to 77 years presented with adenoid cystic carcinomas (n = 9), squamous cell carcinomas (n = 6), and other airway tumors (n = 10).
  • Four (16%) patients died of disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Carcinoma, Squamous Cell / surgery. Chondrosarcoma / surgery. Cough / etiology. Deglutition Disorders / etiology. Dyspnea / etiology. Hemoptysis / etiology. Hoarseness / etiology. Humans. Massachusetts / epidemiology. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / etiology. Pain / etiology. Respiratory Sounds / etiology. Retrospective Studies. Sarcoma / surgery. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867773.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Seikaly H, Rieger J, O'Connell D, Ansari K, Alqahtani K, Harris J: Beavertail modification of the radial forearm free flap in base of tongue reconstruction: technique and functional outcomes. Head Neck; 2009 Feb;31(2):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Head and neck oncologists are often confronted with the difficult challenge of balancing cancer cure with the preservation of function when deciding the patient's best treatment protocol.
  • This task is especially difficult in cancer of the base of tongue.
  • METHODS: Thirty-one consecutive patients treated for base of tongue cancer with primary surgery were followed prospectively.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps. Tongue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073000.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Subhashraj K, Orafi M, Nair KV, El-Gehani R, Elarbi M: Primary malignant tumors of orofacial region at Benghazi, Libya: a 17 years review. Cancer Epidemiol; 2009 Nov;33(5):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the epithelial tumors, squamous cell carcinoma (50.6%) was the most common neoplasm, followed by mucoepidermoid carcinoma (15%) and adenoid cystic carcinoma (8.7%).

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932650.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


11. Güerrissi JO, Quiroga JP: Adnexal carcinomas of the head and neck. Indian J Plast Surg; 2008 Jul;41(2):229-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal carcinomas of the head and neck.
  • Adnexal carcinomas of the skin are rare and they derive from structures such as sweat glands, sebaceous glands, and hair follicles.
  • Adnexal tumors represent 1-2% of skin cancers.
  • Four (50%) of them had malignant cylindromas, two (25%) had sebaceous carcinoma, and the other two (25%) syringoid eccrine carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatologica. 1980;160(6):361-70 [6248388.001]
  • [Cites] Br J Plast Surg. 1990 Nov;43(6):702-5 [2175228.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Jun;25(3):196-8 [8872222.001]
  • [Cites] Ann Plast Surg. 1996 Feb;36(2):194-6 [8919387.001]
  • [Cites] Semin Cutan Med Surg. 1999 Sep;18(3):233-43 [10468043.001]
  • [Cites] Histopathology. 1980 Jul;4(4):445-66 [6253380.001]
  • [Cites] Genet Couns. 2004;15(2):175-82 [15287417.001]
  • (PMID = 19753272.001).
  • [ISSN] 0970-0358
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2740523
  • [Keywords] NOTNLM ; Adnexal carcinomas / adnexal tumors / skin cancer
  •  go-up   go-down


12. Luukkaa H, Laitakari J, Vahlberg T, Klemi P, Stenbäck F, Grénman R: Morphometric analysis of CD34-positive vessels in salivary gland adenoid cystic and mucoepidermoid carcinomas. J Oral Pathol Med; 2009 Oct;38(9):695-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometric analysis of CD34-positive vessels in salivary gland adenoid cystic and mucoepidermoid carcinomas.
  • BACKGROUND: Carcinomas of the salivary glands are uncommon and morphologically a diverse group of malignancies.
  • To evaluate the prognostic value of CD34 immunostaining of the vessels in adenoid cystic carcinoma (AdCC) and mucoepidermoid carcinoma (MEC), an automated image analysis method was used.
  • METHOD: In a nationwide study, covering salivary gland cancer (SGC) patients in Finland 1991-1996, 37 AdCC and 18 MEC patients (M 25, F 30, age 25-90, mean 63) were included.
  • Of the total tumor vessels measured, 2651 were from patients who deceased with disease (Group I) and 4397 were from specimens derived from those who did not die of disease (Group II) during the 10-year follow-up.
  • In MEC, the Group I patients had a higher staining intensity among high-grade patients compared with patients with low grade disease, whereas the tumors in Group II had a lower staining intensity among the high-grade compared with the low grade tumors (P = 0.018).
  • [MeSH-major] Antigens, CD34 / immunology. Carcinoma, Adenoid Cystic / blood supply. Carcinoma, Mucoepidermoid / blood supply. Image Processing, Computer-Assisted. Microvessels / immunology. Neovascularization, Pathologic / immunology. Salivary Gland Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19674249.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


13. Cantù G, Riccio S, Bimbi G, Squadrelli M, Colombo S, Compan A, Rossi M, Pompilio M, Solero CL: Craniofacial resection for malignant tumours involving the anterior skull base. Eur Arch Otorhinolaryngol; 2006 Jul;263(7):647-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While almost everything has been written about technical details, few studies reported meaningful analysis about prognostic factors and long-term results, for a series of reasons: the infrequency of these tumours, the variety of histologies, small patients cohorts presented by each author, a medley of untreated and pre-treated patients, the lack of a universally accepted classification.
  • [MeSH-major] Carcinoma / surgery. Cranial Fossa, Anterior / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / surgery. Carcinoma, Adenoid Cystic / classification. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / surgery. Ethmoid Sinus. Humans. Prognosis. Skull Base / surgery. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2002 Nov;119(5):271-80 [12464852.001]
  • [Cites] Br Med J. 1970 Feb 14;1(5693):385-93 [5434656.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Apr;118(4):367-72 [1313248.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Mar;115(3):301-7 [2917065.001]
  • [Cites] Laryngoscope. 1979 Jul;89(7 Pt 1):1077-91 [449551.001]
  • [Cites] Neurochirurgie. 1997;43(2):100-10 [9296053.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Nov;125(11):1252-7 [10555698.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):385-93 [8457302.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2005 Feb;13(1):50-4 [15654216.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Head Neck. 1999 Jan;21(1):12-20 [9890346.001]
  • [Cites] J Neurosurg. 1968 Apr;28(4):341-50 [5643926.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Sep;118(9):913-7 [1503715.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):481-4 [7977980.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):3-10 [8125786.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):406-13 [4051102.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1203-8 [7917203.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Br Med J. 1968 Jun 8;2(5605):587-96 [5654629.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1991 Mar;101(3):240-4 [2000010.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2005 Feb;13(1):32-8 [15654213.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Cancer. 1954 Sep;7(5):991-4 [13199776.001]
  • [Cites] Head Neck. 1999 May;21(3):185-91 [10208659.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1296-304; discussion 1304-5 [11126900.001]
  • [Cites] Laryngoscope. 1999 Dec;109(12):1959-66 [10591355.001]
  • [Cites] Head Neck. 1998 May;20(3):193-6 [9570623.001]
  • [Cites] Am J Surg. 1973 Oct;126(4):469-76 [4743833.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):995-1001; discussion 1001 [15340811.001]
  • [Cites] Laryngoscope. 1994 Aug;104(8 Pt 1):940-5 [8052078.001]
  • [Cites] Head Neck. 2005 Jun;27(6):445-51 [15825205.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Aug;24(4):199-203 [15688904.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Dec;123(12):1312-7 [9413360.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Arch Otolaryngol. 1977 Sep;103(9):514-7 [332133.001]
  • [Cites] Head Neck. 2005 Mar;27(3):224-31 [15627260.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • [Cites] Am J Surg. 1966 Oct;112(4):591-6 [5915306.001]
  • (PMID = 16538505.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


1
Advertisement
4. Santos RR, Damasceno RW, de Pontes FS, Cursino SR, Nishiwaki-Dantas MC, Vital Filho J, Dantas PE: Ten-year follow-up of a case series of primary epithelial neoplasms of the lacrimal gland: clinical features, surgical treatment and histopathological findings. Arq Bras Oftalmol; 2010 Jan-Feb;73(1):33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year follow-up of a case series of primary epithelial neoplasms of the lacrimal gland: clinical features, surgical treatment and histopathological findings.
  • PURPOSE: To describe and analyze the features of a cases series of patients with primary epithelial neoplasms of the lacrimal gland, its surgical treatment, and histopathological findings.
  • RESULTS: During the study period, there were 12 patients, 5 (41.7%) with benign tumors, all pleomorphic adenomas (benign mixed tumor) and 7 (58.3%) with malignant neoplasms, thus distributed: four cases of adenoid cystic carcinoma, two of mucoepidermoid carcinoma and one carcinoma expleomorphic adenoma.
  • Three patients developed distant metastasis and died of disease.
  • CONCLUSIONS: The most frequent primary epithelial neoplasms of the lacrimal gland were pleomorphic adenoma and adenoid cystic carcinoma during the study period.
  • The histopathological diagnosis and the disease initial stage can play a significant role in patient's survival.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / pathology. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / pathology

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464111.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


15. Zhang N, Zhang DS, Han JQ, Zhang SZ, Liu GJ, Wei FC, Zhang J, Mu WL: [Radiosensitization by double suicide gene system in ACC-2 cell]. Shanghai Kou Qiang Yi Xue; 2009 Apr;18(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the radiosensitization by prodrug and CD-TK double suicide gene therapy system in adenoid cystic carcinoma cells (ACC-2).
  • [MeSH-minor] Carcinoma, Adenoid Cystic. Cell Line, Tumor. Genetic Therapy. Humans. Plasmids. Transfection. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417997.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase; EC 3.5.4.1 / Cytosine Deaminase
  •  go-up   go-down


16. Dequanter D, Andry G, Lothaire P, Larsimont D, Deraemaecker R: Wide localized excision and reconstruction for minor salivary gland tumours. B-ENT; 2005;1(4):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four consecutive patients suffering from minor salivary gland tumours of the upper aerodigestive tract were treated: two had adenoid cystic carcinomas (one of the lateral oropharyngeal mucosa, one of the retromolar area); one had a polymorphous low-grade carcinoma (at the base of the tongue); and one had mucoepidermoid carcinoma (on the floor of the mouth).
  • Two patients, locally controlled, with adenoid cystic carcinomas died: one from brain metastases (four years post-surgery), the other with pulmonary metastases (eight-years post-surgery).
  • One patient is alive with a recurrent tumour of the pterygomaxillary fossa (without trismus) sixteen years after the original operation; another patient is free of recurrent disease at the base of the tongue but has recently undergone surgery, with success, for two pulmonary metastases sixty months after the initial surgery.
  • CONCLUSIONS: For minor salivary gland carcinoma of the head and neck, large resection with immediate reconstruction affords fast recovery and long-lasting locoregional control.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neck Dissection / methods. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429751.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


17. Ayadi K, Ayadi L, Daoud E, Mnif Z, Ben Mahfoudh K, Boudawara T, Mnif J: Adenoid cystic carcinoma of the parotid with facial nerve invasion. Tunis Med; 2010 Jan;88(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the parotid with facial nerve invasion.
  • BACKGROUND: Adenoid cystic carcinoma comprises approximately 10% of all epithelial salivary neoplasms and most frequently involves the parotid.
  • AIM: The authors report a case of parotid adenoid cystic carcinoma with invasion and spread via the facial nerve with an emphasis on radiologic features.
  • OBSERVATION: We report a case of a 47-year-old man presenting with a right submandibular mass evolving for 4 years.
  • Pathologic examination of the resected specimen revealed histological features of adenoid cystic carcinoma with intra neural invasion of the mastoid segment of the facial nerve.
  • CONCLUSION: This study confirms that multiplanar approach of MRI allows rapid detection of adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Facial Nerve / pathology. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415214.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


18. Mataix J, Bañuls J, Botella R, Laredo C, Lucas A: [Brooke-Spiegler syndrome: an heterogeneous entity]. Actas Dermosifiliogr; 2006 Dec;97(10):669-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Síndrome de Brooke-Spiegler: una entidad heterogénea.
  • The Brooke-Spiegler syndrome is a rare, autosomally dominant disease with a predisposition to develop different adnexal tumors.
  • Clinically it is characterized by the presence of multiple cylindromas, trichoepitheliomas, and occasionally, spiradenomas.
  • In this article we present the case of a woman and her daughter, both affected by this rare genodermatosis.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Neoplasms, Basal Cell / genetics. Neoplasms, Multiple Primary / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Child. Facial Neoplasms / diagnosis. Facial Neoplasms / genetics. Female. Genes, Dominant. Humans. Phenotype

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173833.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 30
  •  go-up   go-down


19. Musani MA, Sohail Z, Zafar S, Malik S: Morphological pattern of parotid gland tumours. J Coll Physicians Surg Pak; 2008 May;18(5):274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenoma was most common benign tumor (83.5%), followed by Warthins tumour.
  • The most common malignant tumour was mucoepidermoid carcinoma (60%), followed by adenoid cystic carcinoma.
  • Parotid swelling for years was main feature of benign tumours, whereas malignant tumours presented with pain, fixation to skin or underlying structure, cervical lymphadenopathy and facial palsy.
  • CONCLUSION: Pleomorphic adenoma was the most common benign tumour and mucoepidermoid carcinoma was most common malignant tumour.
  • [MeSH-major] Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Fine-Needle. Child. Diagnosis, Differential. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Morbidity / trends. Neoplasm Staging / methods. Pakistan / epidemiology. Retrospective Studies. Severity of Illness Index. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541080.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Pakistan
  •  go-up   go-down


20. Moore BA, Burkey BB, Netterville JL, Butcher RB 2nd, Amedee RG: Surgical management of minor salivary gland neoplasms of the palate. Ochsner J; 2008;8(4):172-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common malignant tumor encountered was low grade polymorphous adenocarcinoma, followed by mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dentomaxillofac Radiol. 1997 Jan;26(1):16-21 [9446985.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Jun;121(6):607-12 [7772309.001]
  • [Cites] Head Neck. 1998 Dec;20(8):699-706 [9790291.001]
  • [Cites] Arch Otolaryngol. 1978 Sep;104(9):501-4 [210749.001]
  • [Cites] Ear Nose Throat J. 1989 Feb;68(2):137-40 [2656236.001]
  • [Cites] Am J Otolaryngol. 1989 Jul-Aug;10(4):250-6 [2764237.001]
  • [Cites] Laryngoscope. 1987 Nov;97(11):1343-5 [2823035.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33 [2845326.001]
  • [Cites] Laryngoscope. 1980 Apr;90(4):576-84 [6767146.001]
  • [Cites] Laryngoscope. 1995 Nov;105(11):1155-60 [7475867.001]
  • [Cites] J Oral Maxillofac Surg. 1994 May;52(5):454-9 [8169706.001]
  • [Cites] J Laryngol Otol. 1993 Sep;107(9):858-61 [8228611.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Mar;108(3):304-5 [8385307.001]
  • [Cites] J Okla Dent Assoc. 1996 Spring;86(4):50-2 [9540689.001]
  • [Cites] Histopathology. 1998 Jun;32(6):521-9 [9675591.001]
  • [Cites] Otolaryngol Clin North Am. 1999 Oct;32(5):875-86 [10477793.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):548-52 [10547468.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1319-28 [11023093.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):837-41 [11448360.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):946-51 [12782803.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):935-42 [6692293.001]
  • [Cites] Acta Cytol. 1998 Jul-Aug;42(4):888-98 [9684573.001]
  • (PMID = 21603498.001).
  • [ISSN] 1524-5012
  • [Journal-full-title] The Ochsner journal
  • [ISO-abbreviation] Ochsner J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3096363
  • [Keywords] NOTNLM ; Palate / salivary gland neoplasms
  •  go-up   go-down


21. Chu WF, Wu DM, Liu W, Wu LJ, Li DZ, Xu DY, Wang XF: Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. Oral Oncol; 2009 Nov;45(11):998-1004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma.
  • New chemotherapeutic strategy should be investigated to enhance clinical management in salivary gland adenoid cystic carcinoma (ACC).
  • Recently, sulforaphane (SFN), as a natural compound from cruciferous vegetables exhibits a potent anti-cancer activity in various tumor cells, but remains uncertain in ACC cells.
  • Cell survives, apoptosis, cell cycle progression and molecular targets were identified by multiple detecting techniques, including trypan blue dye exclusion assay, electron microscopy, AO/EB staining, flow cytometry and immunoblotting in human lung high metastasis cell line of salivary gland adenoid cystic carcinoma (ACC-M).
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Carcinoma, Adenoid Cystic / drug therapy. Lung Neoplasms / drug therapy. Salivary Gland Neoplasms / drug therapy. Thiocyanates / pharmacology


22. Yasuda M, Hanagiri T, Ichiki Y, Uramoto H, Takenoyama M, Yasumoto K: Surgical treatment of patients with stenosis of the central airway due to tracheal tumours. Asian J Surg; 2010 Oct;33(4):212-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histological finding was thyroid carcinoma (n = 3), followed by adenoid cystic carcinoma (n = 2), a metastatic thyroid tumour (n = 1), and a benign granular cell tumour (n = 1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21377110.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • Twenty-nine of 60 (48%) clear cell carcinomas showed a mucoid stroma, either focally (21 cases) or diffusely (8 cases).
  • The mucoid stroma in clear cell carcinomas was distinct from that in other surface epithelial tumors as follows: it showed a compact spherule-like appearance, commonly occupying the cores of small papillae.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • Among 40 clear cell carcinomas that had at least one type of stroma, 26 (65%) had both, either concomitantly or separately.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


24. Miettinen M, Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):205-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD117 (KIT) is a type III receptor tyrosine kinase operating in cell signal transduction in several cell types.
  • Other KIT-positive normal cells include epithelial cells in skin adnexa, breast, and subsets of cerebellar neurons.
  • Also, KIT is expressed in pulmonary and other small cell carcinomas, adenoid cystic carcinoma, renal chromophobe carcinoma, thymic, and some ovarian and few breast carcinomas.
  • KIT deficiency due to hereditary nonsense/missense mutations leads to disruption of KIT-dependent functions such as erythropoiesis, skin pigmentation, fertility, and gastrointestinal motility.
  • KIT tyrosine kinase inhibitors such as imatinib mesylate are the generally accepted treatment of metastatic GISTs, and their availability has prompted an active search for other treatment targets among KIT-positive tumors such as myeloid leukemias and small cell carcinoma of the lung, with variable and often nonconvincing results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082245.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 239
  •  go-up   go-down


25. Bittner N, Koh WJ, Laramore GE, Patel S, Mulligan MS, Douglas JG: Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy.
  • PURPOSE: To examine the efficacy of fast neutron radiotherapy in the treatment of locally advanced adenoid cystic carcinoma (ACC) of the trachea and to compare outcomes with and without high-dose-rate (HDR) endobronchial brachytherapy boost.
  • CONCLUSIONS: Fast neutron radiotherapy is an effective treatment for locally advanced adenoid cystic carcinoma of the trachea, with acceptable treatment-related toxicity.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Neutrons / therapeutic use. Tracheal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374509.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


26. Wang J, Wang R, Yang W: [Surgical management of nasal septum malignant tumor]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jul;19(14):636-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathology of nasal septum malignant tumor in our department were: seven cases with squamous cell carcinoma in (5 cases were primary, 2 cases were secondary), 4 cases with adenoid cystic carcinoma (3 cases were primary, 1 case was secondary), 3 cases with malignant melanoma, 1 case with adenocarcinoma, 1 case with mucoepidermoid carcinoma.
  • After follow up for 1-10 years, 1 case was undetected, 2 cases were dead (1 case with malignant melanoma, 1 case with secondary squamous cell cancer), 3 cases survive with tumor (1 case with squamous cell cancer, 1 case with secondary adenoid cystic cancer, 1 case with malignant melanoma).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Nasal Septum / surgery. Nose Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248459.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • Recurrence of tumor occurred in 4 cases, and 1 case died from distant metastasis of adenocarcinoma.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Moore MG, Deschler DG, McKenna MJ, Varvares MA, Lin DT: Management outcomes following lateral temporal bone resection for ear and temporal bone malignancies. Otolaryngol Head Neck Surg; 2007 Dec;137(6):893-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this group of 35 patients, the mean age was 62.7 years, with tumor histopathologies including squamous cell carcinoma (SCC, 20), basal cell carcinoma (BCC, 7), adenoid cystic carcinoma (ACC, 7), and adenocarcinoma (1).
  • The 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were 77%, 79%, and 52%, respectively.
  • CONCLUSIONS: In patients with carcinomas of the ear and temporal bone, upfront excision including LTBR is an effective management when combined with postoperative radiation therapy.
  • Complete removal of all disease may improve survival and decrease recurrence.
  • [MeSH-minor] Adenocarcinoma / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Ear Canal / surgery. Ear, External / surgery. Ear, Middle / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Parotid Gland / surgery. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036417.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK: Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys; 2006 Nov 15;66(4):1044-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas.
  • METHODS AND MATERIALS: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy).
  • Histology was: 14 mucoepidermoid (31%), 10 adenocarcinoma (22%), 8 adenoid cystic (18%), 4 undifferentiated (9%), 4 acinic (9%), 2 malignant mixed (4%), 2 squamous (4%), and 1 salivary duct carcinoma (2%).
  • No patient had clinical or pathologic evidence of lymph node disease.
  • A Cox proportional hazard model identified T3-4 disease (p = 0.004) and radiation dose lower than 66 Gy (p = 0.001) as independent predictors of local recurrence.
  • [MeSH-major] Carcinoma / radiotherapy. Salivary Gland Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965870.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Jensen AD, Krauss J, Weichert W, Debus J, Münter MW: RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol; 2010;5:102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.
  • BACKGROUND: Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carbon Radioisotopes / therapeutic use. Carcinoma, Adenoid Cystic / radiotherapy. Heavy Ions / therapeutic use. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Disease-Free Survival. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Am J Clin Oncol. 2011 Feb;34(1):76-81 [20177363.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):14-7 [11669550.001]
  • [Cites] Head Neck. 2002 Jul;24(7):632-6 [12112535.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Head Neck. 2004 Feb;26(2):154-62 [14762884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64 [15380567.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2869-72 [2824016.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2313-9 [3179947.001]
  • [Cites] Head Neck. 1992 Jul-Aug;14(4):273-7 [1381339.001]
  • [Cites] Cancer. 1994 May 15;73(10):2563-9 [8174054.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11 [15629600.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1278-82 [15995521.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):338-44 [15937907.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):153-7 [16601434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9 [16904520.001]
  • [Cites] Radiat Oncol. 2006;1:17 [16756669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9 [17116822.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2696-705 [17121916.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1044-50 [16965870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7 [17241753.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1365-72 [18029108.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5518-23 [18936479.001]
  • [Cites] Oral Oncol. 2009 Jul;45(7):574-8 [18804410.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-92 [19620591.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):308-11 [20385414.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Dec;14(6):451-63 [10850332.001]
  • (PMID = 21047402.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Carbon Radioisotopes; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2987937
  •  go-up   go-down


31. Handra-Luca A, Planchard D, Fouret P: Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation. Oral Oncol; 2009 Nov;45(11):e208-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Adenoid Cystic / therapy. Maxillary Sinus Neoplasms / therapy. Mouth Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Radiotherapy, Conformal. Taxoids / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502105.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Blake PW, Toro JR: Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat; 2009 Jul;30(7):1025-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the cylindromatosis (CYLD) gene have been described in families with cylindromas, trichoepitheliomas, and/or spiradenomas.
  • Brooke-Spiegler syndrome (BSS) is the autosomal dominant predisposition to skin appendageal neoplasms including cylindromas, trichoepitheliomas, and/or spiradenomas.


33. Vranić S, Bilalović N, Lee LM, Kruslin B, Lilleberg SL, Gatalica Z: PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol; 2007 Sep;38(9):1425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
  • Adenoid cystic carcinoma (ACC) of the breast rarely metastasizes and has been associated with excellent prognosis.
  • A detailed molecular genetic analysis of the primary and metastatic tumors demonstrated somatic mutations in 2 well-known cancer genes associated with regulation of PI3K/AKT signaling pathway:.


34. Lai FY, Zhang Q, Wu QL, Qing J, Cao Y: [Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands]. Ai Zheng; 2007 Sep;26(9):1025-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands].
  • This study was to explore the expression of E-cadherin in adenoid cystic carcinoma of the salivary glands and its correlations to nerve invasion, regional recurrence, distant metastasis and prognosis of this disease.
  • METHODS: The expression of E-cadherin in 55 specimens of adenoid cystic carcinoma of the salivary glands and 20 specimens of normal salivary gland tissue was detected by immunohistochemistry.
  • The positive rate of E-cadherin was significantly higher in normal salivary gland tissues than in adenoid cystic carcinoma tissues (90.0% vs.63.6%, P<0.05).
  • CONCLUSION: E-cadherin expression is down-regulated in adenoid cystic carcinoma of the salivary glands, which is correlated to nerve invasion, regional recurrence and distant metastasis.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Adenoid Cystic / metabolism. Salivary Gland Neoplasms / metabolism


35. Otsuka H, Graham MM, Kogame M, Nishitani H: The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med; 2005 Dec;19(8):691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma.
  • RESULTS: In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma).
  • Three patients (25%) had FDG positive distant disease (liver, bone, lymph nodes); surgery was canceled and therapy changed to chemoradiation.
  • In the restaging group (33 studies in 23 patients), 5 patients (22%) had FDG positive distant disease, which changed the treatment from surgery to chemoradiation or other.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444995.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Zhengjaiang L, Pingzhang T, Dechao Z, Reddy-Kolanu G, Ilankovan V: Primary tracheal tumours: 21 years of experience at Peking Union Medical College, Beijing, China. J Laryngol Otol; 2008 Nov;122(11):1235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-nine patients had malignant tumours, most commonly adenoid cystic carcinoma (50.7 per cent) or squamous cell carcinoma (30.4 per cent).
  • The five-year survival rates for adenoid cystic carcinoma and squamous cell carcinoma were 40.2 and 24.6 per cent, respectively.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / therapy. Tracheal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331654.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R: Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer. Acta Otolaryngol; 2008 Apr;128(4):482-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer.
  • CONCLUSIONS: In the current study matrix metalloproteinases (MMPs)-9 and -13 were associated with the prognosis in salivary gland cancer (SGC), indicating that they contribute to the progression and invasion of these malignant tumours.
  • OBJECTIVES: Elevated levels of certain MMPs have been detected in various advanced human cancer types.
  • High MMP-13 intensity (2+3 vs 1; p=0.05), percentage (2 vs 1; p=0.03) and index (3 vs 1; p=0.02) were associated with poor survival in acinic cell carcinoma.
  • However, high MMP-9 index in adenoid cystic carcinoma (p=0.06) and the percentage of positively staining cells in salivary duct carcinoma patients (p=0.05) was associated with poor survival.
  • [MeSH-major] Carcinoma / enzymology. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 13 / metabolism. Matrix Metalloproteinase 9 / metabolism. Salivary Gland Neoplasms / enzymology

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368586.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


38. Kassam AB, Prevedello DM, Carrau RL, Snyderman CH, Gardner P, Osawa S, Seker A, Rhoton AL Jr: The front door to meckel's cave: an anteromedial corridor via expanded endoscopic endonasal approach- technical considerations and clinical series. Neurosurgery; 2009 Mar;64(3 Suppl):ons71-82; discussion ons82-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent abnormalities encountered were adenoid cystic carcinoma, meningioma, and schwannomas.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Cranial Fossa, Middle / surgery. Endoscopy / methods. Meningioma / surgery. Nasal Cavity / surgery. Neurilemmoma / surgery. Neurosurgical Procedures / methods. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240575.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Retamar RA, Stengel F, Saadi ME, Kien MC, Della Giovana P, Cabrera H, Chouela EN: Brooke-Spiegler syndrome - report of four families: treatment with CO2 laser. Int J Dermatol; 2007 Jun;46(6):583-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Brooke-Spiegler syndrome is a well known but rare cutaneous disorder characterized by the presence of multiple trichoepitheliomas and cylindromas.
  • [MeSH-major] Adenoma, Sweat Gland / surgery. Carcinoma, Adenoid Cystic / surgery. Laser Therapy. Neoplasms, Adnexal and Skin Appendage / surgery. Neoplasms, Multiple Primary / surgery. Neoplastic Syndromes, Hereditary / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550556.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, Adams JA, Lopes VV, Varvares M, Loeffler JS, Chan AW: Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg; 2006 Nov;132(11):1242-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton beam radiation therapy for skull base adenoid cystic carcinoma.
  • OBJECTIVE: To determine the treatment outcome and prognostic factors in patients with adenoid cystic carcinoma of the skull base treated with proton beam radiation therapy.
  • PATIENTS: From 1991 to 2002, 23 patients with newly diagnosed adenoid cystic carcinoma with skull base extension were treated with combined proton and photon radiotherapy.
  • MAIN OUTCOME MEASURES: Locoregional control and disease-free survival and overall survival rates.
  • The disease-free and overall survival rates at 5 years were 56% and 77%, respectively.
  • CONCLUSIONS: High-dose conformal proton beam radiation therapy results in a very encouraging local control rate in patients with adenoid cystic carcinoma of the skull base.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carbon. Cavernous Sinus. Cranial Fossa, Posterior. Disease-Free Survival. Female. Humans. Male. Middle Aged. Nasopharyngeal Neoplasms / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neutrons. Paranasal Sinus Neoplasms / pathology. Prognosis. Protons. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy. Sphenoid Sinus. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116822.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 7440-44-0 / Carbon
  •  go-up   go-down


41. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol; 2005 Jan 20;23(3):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
  • PURPOSE: This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit.
  • A high level of c-kit expression has been identified in more than 90% of ACCs.
  • Nine patients had stable disease as best response.
  • Six patients had progressive disease after two cycles.
  • Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC.
  • Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • (PMID = 15659505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM 17102-01; United States / NCI NIH HHS / CM / N01 CM 17107-01
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


42. Lee C, Langen KM, Lu W, Haimerl J, Schnarr E, Ruchala KJ, Olivera GH, Meeks SL, Kupelian PA, Shellenberger TD, Mañon RR: Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys; 2008 Aug 1;71(5):1563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration.
  • PURPOSE: To analyze changes in parotid gland dose resulting from anatomic changes throughout a course of radiotherapy in a cohort of head-and-neck cancer patients.
  • METHODS AND MATERIALS: The study population consisted of 10 head-and-neck cancer patients treated definitively with intensity-modulated radiotherapy on a helical tomotherapy unit.
  • [MeSH-minor] Algorithms. Carcinoma, Adenoid Cystic / radiography. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Humans. Radiotherapy Dosage. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538505.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


44. Chen AM, Garcia J, Granchi PJ, Johnson J, Eisele DW: Late recurrence from salivary gland cancer: when does "cure" mean cure? Cancer; 2008 Jan 15;112(2):340-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence from salivary gland cancer: when does "cure" mean cure?
  • BACKGROUND: The purpose of the current study was to determine the incidence of late recurrences, which were defined as those occurring >or=5 years after initial therapy, among patients treated for salivary gland cancer.
  • METHODS: Between 1960 and 2000, 145 patients underwent definitive therapy for localized carcinomas of the salivary glands and were clinically without evidence of disease at 5 years of follow-up.
  • RESULTS: The 10-year and 15-year cumulative probabilities of late recurrence in patients who were free of disease at 5 years were 13% and 18%, respectively.
  • The crude rates of late recurrence by histologic subtype were adenoid cystic carcinoma (26%), mixed malignant tumor (25%), mucoepidermoid carcinoma (17%), adenocarcinoma (10%), and acinic cell carcinoma (8%).
  • Salvage treatment varied according to location of disease recurrence and initial treatment characteristics.
  • The 15-year estimate of overall survival was 39% for patients who experienced a late recurrence compared with 71% for those who remained free of disease (P= .001).
  • CONCLUSIONS: A significant proportion of patients who are presumed to be cured of their disease at 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrence with additional follow-up.


45. Dräger H, Kruse R, Reifenberger J, Meyer U, Schulte KW: [Cylindromatosis]. Hautarzt; 2006 Apr;57(4):332-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Scalp. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Comorbidity. Dermatologic Surgical Procedures. Female. Humans. Middle Aged. Skin / pathology. Skin Diseases, Bacterial / diagnosis. Skin Diseases, Bacterial / pathology. Superinfection / diagnosis. Superinfection / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Jun;25(2):160-5 [10835629.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):797-801 [12917690.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):441-3 [7493027.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1618-23 [7688655.001]
  • (PMID = 16523269.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, Zhao YF: Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis; 2010 Jul;15(7):850-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin.
  • The present study was to investigate the effects of quercetin on growth and apoptosis in human salivary adenoid cystic carcinoma (ACC).
  • [MeSH-major] Antineoplastic Agents / toxicity. Apoptosis. Carcinoma, Adenoid Cystic / metabolism. Quercetin / toxicity. Salivary Gland Neoplasms / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20386985.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-43-6 / Cytochromes c; 9IKM0I5T1E / Quercetin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.10 / I-kappa B Kinase; EC 3.4.22.- / Caspases
  •  go-up   go-down


47. Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P: P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract; 2005;200(11-12):791-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up.
  • Adenoid cystic carcinoma (ACC) is an indolent tumor that pursues a protracted clinical course with recurrences and late metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Ki-67 Antigen / metabolism. Palatal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792122.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA: Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol; 2009 Oct;31(5):280-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Immunohistochemical expression of epidermal growth factor (EGF), EGFR, ErbB-2, fatty acid synthase (FAS) and Ki-67 were analyzed in 41 pleomorphic adenoma (PA), in 30 mucoepidermoid carcinoma (MEC) and in 30 adenoid cystic carcinoma (ACC) and correlated with their histologic patterns.


49. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol; 2005 Sep 1;23(25):6271-3; author reply 6273-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • (PMID = 16135502.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


50. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • It is also characterized by the presence of a slack and hyaline stroma and the absence of myxoid or condroid stroma.
  • In contrast to pleomorphic adenoma, it tends to be multiple and its recurrence rate after surgical excision is high.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.
  • [MeSH-major] Adenoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


51. Ramer N, Wu H, Sabo E, Ramer Y, Emanuel P, Orta L, Burstein DE: Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer; 2010 Jan 1;116(1):77-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis.
  • BACKGROUND: In a long-term retrospective immunohistochemical study of adenoid cystic carcinoma (ACC) of salivary gland, we investigated the relation of p63 immunodetection to prognosis.
  • Automated image analysis was used to quantify p63 positivity, using a modification of a previously developed algorithm.
  • RESULTS: Patients alive for more than 10 years had a lower extent of p63 expression than those who died of disease.
  • Kaplan-Meier analysis revealed that separation of patients with morbidity and mortality from those alive with no evidence of disease, could be achieved at a cutoff of 35% p63 positivity (P = .0031, log-rank test).
  • CONCLUSIONS: To our knowledge, the present study is the first to report prognostic significance of p63 in salivary gland ACC and the first report of a robust and well-studied immunohistochemical stain performable on routinely fixed and processed tissue with prognostic utility.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / diagnosis. Membrane Proteins / analysis. Salivary Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • (PMID = 19877114.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


52. Murphy JG, Lonsdale R, Premachandra D, Hellquist HB: Salivary hybrid tumour: adenoid cystic carcinoma and basal cell adenocarcinoma. Virchows Arch; 2006 Feb;448(2):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary hybrid tumour: adenoid cystic carcinoma and basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):494-6 [10747300.001]
  • [Cites] Histopathology. 1999 Oct;35(4):380-3 [10564394.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):698-702 [10420226.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Jul;260(6):312-5 [12883954.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):425-8 [15480772.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):724-33 [12118110.001]
  • [Cites] Histopathology. 2000 Sep;37(3):283-4 [10971706.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):495-500 [9230915.001]
  • [Cites] J Korean Med Sci. 2004 Jun;19(3):462-5 [15201517.001]
  • (PMID = 16411133.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


53. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M: Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol; 2005 Feb;27(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation.
  • Brooke-Spiegler syndrome is an autosomal dominantly inherited disease with predisposition to cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.
  • The histopathological spectrum in our patient included cylindromas, spiradenomas, trichoepitheliomas, small nodular trichoblastomas, and lymphadenomas.
  • The occurrence of sebaceous and trichoblastic differentiation in spiradenocylindromas is a further proof that spiradenoma and cylindroma are not eccrine tumors but neoplasms of the folliculosebaceousapocrine unit.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Neoplasms, Multiple Primary / pathology. Neoplastic Syndromes, Hereditary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenoma, Sweat Gland / metabolism. Adenoma, Sweat Gland / pathology. Adenoma, Sweat Gland / surgery. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Diseases / surgery. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunoenzyme Techniques. Male. Sebaceous Glands / metabolism. Sebaceous Glands / pathology. Syndrome

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677973.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Badakhshi H, Marnitz S, Scherer H, Budach V, Haisch A: [Adenoid cystic carcinoma of the oropharynx. Brachytherapy for the treatment of local recurrences]. HNO; 2008 Mar;56(3):328-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the oropharynx. Brachytherapy for the treatment of local recurrences].
  • [Transliterated title] Adenoidzystisches Karzinom des Oropharynx. Brachytherapie zur Behandlung eines lokalen Rezidivs.
  • PURPOSE: Adenoid cystic carcinomas are rare tumours.
  • We report on a safe and effective salvage option in the treatment of adenoid cystic carcinoma.
  • MATERIAL AND METHODS: A 44 year old woman with the diagnosis of adenoid cystic carcinoma of the oropharynx and simultaneous pulmonary metastases received a mixed beam photon radiotherapy and a neutron boost.
  • On the basis of a pretreatment MRI, a single dose of 5 Gy encompassing the palpable tumour was given to a total dose of 15 Gy.
  • CONCLUSION: HDR-Ir brachytherapy is an effective method for the treatment of local recurrences of an adenoid cystic carcinoma, even after preradiotherapy.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Adenoid Cystic / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Oropharyngeal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1990 Mar;19(3):101-7 [2160530.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):235-40 [8407397.001]
  • [Cites] Radiother Oncol. 1990 Jan;17(1):47-56 [2108475.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):2031-3 [2171754.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Feb;10(2):221-3 [6323361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):551-7 [10701733.001]
  • [Cites] Strahlenther Onkol. 1990 Jan;166(1):107-10 [2154043.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Strahlenther Onkol. 1990 Jan;166(1):78-85 [2154052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16 [11240231.001]
  • [Cites] Recent Results Cancer Res. 1998;150:88-99 [9670284.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):747-52 [8391275.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] Strahlenther Onkol. 2003 May;179(5):345-51 [12740662.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):619-26 [7790247.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]
  • (PMID = 18288466.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Ozer E, Bapna S, Agrawal A, Schuller DE: Maxillary removal and reinsertion: a favorable approach for extensive anterior cranial base tumors. Otolaryngol Head Neck Surg; 2010 Mar;142(3):322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute.
  • The most commonly encountered malignant neoplasm was squamous cell cancer (40.3%), followed by esthesioneuroblastoma (24.1%), adenoid cystic cancer (8%), and other neoplasms (27.4%).
  • Overall five-year survival for the patients with squamous cell carcinoma was 62 percent.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Cranial Fossa, Anterior. Otorhinolaryngologic Surgical Procedures / methods. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20172374.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Teymoortash A, Ramaswamy A, Werner JA: [Adenoid cystic carcinoma secondary to heterotopic salivary gland tissue of the cervical lymph nodes]. Laryngorhinootologie; 2007 Jan;86(1):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma secondary to heterotopic salivary gland tissue of the cervical lymph nodes].
  • [Transliterated title] Adenoidzystisches Karzinom im heterotopen Speicheldrüsengewebe der zervikalen Lymphknoten.
  • BACKGROUND: The presence of heterotopic salivary gland tissue in intra-, periparotideal and cervical lymph nodes is not an uncommen finding.
  • The histological assessment of the extirpated node seemed to indicate lymph node metastasis of an adenoid cystic carcinoma.
  • RESULTS: Due to the fact of missing of a primary tumor, the diagnosis of an adenoid cystic carcinoma in heterotopic salivary gland tissue of the cervical lymph node was established after long-term observation.
  • CONCLUSION: After exclusion of an occult carcinoma of the salivary glands, the possibility of malignant transformation of heterotopic intranodal salivary gland inclusions should be considered in patients suffering from salivary gland carcinoma in the area of the cervical lymph nodes.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cell Transformation, Neoplastic / pathology. Choristoma / pathology. Lymph Nodes / pathology. Otorhinolaryngologic Neoplasms / pathology. Salivary Glands
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16586289.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Huang ZQ, Chen WL, Li HG, Li JS, Xu ZY, Lin ZY: Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. J Craniofac Surg; 2010 Nov;21(6):1855-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular matrix metalloproteinase inducer expression in mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher than in normal salivary gland tissues and pleomorphic adenomas (P < 0.05).
  • The MVD of mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher compared with pleomorphic adenomas (P < 0.05).
  • [MeSH-minor] Adenoma, Pleomorphic / blood supply. Adenoma, Pleomorphic / immunology. Angiogenesis Inducing Agents / analysis. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / blood supply. Carcinoma, Adenoid Cystic / immunology. Carcinoma, Mucoepidermoid / blood supply. Carcinoma, Mucoepidermoid / immunology. Epithelium / blood supply. Epithelium / immunology. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Salivary Ducts / blood supply. Salivary Ducts / immunology. Salivary Glands / blood supply. Salivary Glands / immunology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119439.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


63. Razak AR, Siu LL, Le Tourneau C: Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol; 2010 May;22(3):212-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: The use of cetuximab in squamous cell head and neck cancer is associated with clinical benefit and, in some cases, survival.
  • However, the use of targeted agents beyond cetuximab in this disease remains investigational.
  • Combination therapy of molecular targeted agents with chemoradiation in the locally advanced setting of head and neck squamous cell carcinomas and nasopharyngeal cancer shows early promising results, but at the expense of increased toxicity.
  • The recent identification of improved prognosis among head and neck squamous cell carcinoma patients whose tumors harbor the human papilloma virus may allow better treatment selection for these patients, while the identification of a hallmark gene fusion transcript in adenocystic carcinoma may herald new treatment promise.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Drug Delivery Systems / methods. Head and Neck Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173639.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  • [Number-of-references] 77
  •  go-up   go-down


64. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL: Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck; 2005 Dec;27(12):1022-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
  • BACKGROUND: There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor.
  • Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed.
  • RESULTS: Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks.
  • Three patients died of disease within 6 months.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Adenoid Cystic / drug therapy. Head and Neck Neoplasms / pathology. Lung Neoplasms / drug therapy. Piperazines / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Administration, Oral. Adult. Benzamides. DNA Mutational Analysis. Disease Progression. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Pilot Projects. Pleural Effusion, Malignant / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16265655.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


65. Chang CH, Shu MT, Lee JC, Leu YS, Chen YC, Lee KS: Treatments and outcomes of malignant tumors of external auditory canal. Am J Otolaryngol; 2009 Jan-Feb;30(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Primary cancer of the external auditory canal (EAC) is a rare disease with poor prognosis.
  • METHODS: We retrospectively reviewed the patients treated for primary cancer of EAC between 1991 and 2002 at our hospital, which is a tertiary referral center.
  • RESULTS: Ten patients had squamous cell carcinoma and 2 had adenoid cystic carcinoma (ACC).
  • Five patients had stage I disease, 2 with stage II, 1 with stage III, and 4 with stage IV.
  • All patients (n = 7) with early stage (I or II) were disease-free, but only 1 of 5 patients with late stage (III or IV) was disease-free.
  • Only one patient with complete resection had recurrence and the histologic diagnosis of this particular patient was ACC.
  • CONCLUSIONS: Patients with early-stage cancer can benefit from less aggressive surgical interventions without significant morbidity or mortality.
  • No recurrence occurred in patients with complete resection except the one with ACC.
  • The result of our institute was comparable or superior to those of other studies in early-stage disease.
  • However, patients with advanced cancer had high recurrence rate despite of adjuvant radiotherapy, suggesting more aggressive surgical approach for complete resection was necessary.
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Otologic Surgical Procedures / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027512.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Chijiwa H, Sakamoto K, Umeno H, Nakashima T, Suzuki G, Hayafuchi N: Minor salivary gland carcinomas of oral cavity and oropharynx. J Laryngol Otol Suppl; 2009;(31):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minor salivary gland carcinomas of oral cavity and oropharynx.
  • This paper reviews 22 cases of minor salivary gland carcinoma of the oral cavity or oropharynx which were treated at Kurume University Hospital between 1976 and 2005.
  • Minor salivary gland carcinoma was observed in eight of 362 patients with cancer of the oral cavity (2 per cent), and in 14 of 275 patients with cancer of the oropharynx (5 per cent).
  • The five-year and 10-year survival rates of patients with oropharyngeal minor salivary gland carcinoma were 90 per cent.
  • No statistically significant difference was observed between survival rates for oropharyngeal minor salivary gland carcinoma and for oropharyngeal squamous cell carcinoma (p = 0.06).
  • The five- and 10-year survival rates of patients with oral cavity minor salivary gland carcinoma were 75 and 37 per cent, respectively.
  • No statistically significant difference was observed between survival rates for oral cavity minor salivary gland carcinoma and oral cavity squamous cell carcinoma.Patients' survival results correlated well with the clinical stage of their lesions.
  • In contrast, no significant relationship was found between either survival and tumour type or survival and treatment.
  • Adjuvant therapy is recommended for patients with grade III adenoid cystic carcinoma with perineural infiltration or intravascular infiltration.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Oropharyngeal Neoplasms / mortality. Salivary Gland Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460205.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Vasudev P, Boutross-Tadross O, Radhi J: Basaloid squamous cell carcinoma: two case reports. Cases J; 2009;2:9351
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: two case reports.
  • Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.
  • BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]
  • [Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • (PMID = 20062602.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804002
  •  go-up   go-down


68. Friedrich RE: Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects. Anticancer Res; 2010 May;30(5):1793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal cylindroma of the scalp (turban tumour) and subjacent calvarian defects.
  • This case report describes the diagnosis and therapy of a patient with a 40-year history of multiple potato-like tumours growing in the head and neck region.
  • The tumour proved to be a cylindroma, associated with calvarian defects.
  • A long lasting history of cylindroma and evidence for bone destruction, not associated with a malignant transformation, is extremely rare in Brooke-Spiegler's syndrome.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / pathology. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Angiography / methods. Biopsy. Carotid Arteries / pathology. Female. Humans. Magnetic Resonance Imaging / methods. Skin / pathology. Syndrome. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592381.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


69. Papadogeorgakis N, Kalfarentzos EF, Vourlakou C, Malta F, Exarhos D: Simultaneous pleomorphic adenoma of the left parotid gland and adenoid cystic carcinoma of the contralateral sublingual salivary gland: a case report. Oral Maxillofac Surg; 2009 Dec;13(4):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous pleomorphic adenoma of the left parotid gland and adenoid cystic carcinoma of the contralateral sublingual salivary gland: a case report.
  • Most of the sublingual tumors are malignant, adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC) being the most common histological types.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Sublingual Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1995 Nov;170(5):457-60 [7485732.001]
  • [Cites] Oral Maxillofac Surg. 2009 Mar;13(1):49-53 [19190940.001]
  • [Cites] Radiology. 1982 Oct;145(1):175-7 [6812160.001]
  • [Cites] Arch Otolaryngol. 1974 Aug;100(2):81-90 [4367208.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1986 Aug;11(4):267-91 [3028679.001]
  • [Cites] Am J Surg. 1979 Oct;138(4):579-83 [225961.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2431-7 [1933780.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1219-24 [2917323.001]
  • [Cites] Cancer. 1976 Nov;38(5):2017-21 [186176.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Maxillofac Surg. 1986 Feb;14(1):53-6 [3005457.001]
  • [Cites] Radiol Clin North Am. 1970 Dec;8(3):445-61 [4923905.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):798-802 [6316386.001]
  • (PMID = 19690903.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Messaoudi C, Larouk R, Baili S, Noui B, Benchaoui M, Benkadri H, Belbekri F: [Adenoid cystic carcinoma of the larynx. A case report and review of the literature]. Rev Laryngol Otol Rhinol (Bord); 2007;128(1-2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the larynx. A case report and review of the literature].
  • [Transliterated title] Carcinome adénoïde kystique du larynx. Revue de la littérature, à propos d'un cas.
  • Cylindroma of the head and neck, known as "cystic adenoid carcinoma", begins more often at the expense of the all glandular structures of ectodermic origin, in particularly at the minor and principal salivary glands.
  • RESULTS: The patient is free of disease after six months of follow up.
  • CONCLUSION: The laryngeal cylindroma is rare.
  • The symptomatology does not show a proper characteristic, the diagnosis is a histological finding, and the natural evolution is marked by the very show development of this tumour the onset of cervical lymphatic adenopathy.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Laryngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633677.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 33
  •  go-up   go-down


71. Closmann JJ, Schmidt BL: Adenoid cystic carcinoma manifesting as maxillary jaw pain refractory to conventional treatment: a case report. Gen Dent; 2006 May-Jun;54(3):195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma manifesting as maxillary jaw pain refractory to conventional treatment: a case report.
  • Adenoid cystic carcinoma is an indolent, slow-growing tumor that may first cause low-grade pain in the affected region.
  • This article describes a case involving adenoid cystic carcinoma of the maxilla that was present for approximately nine years.
  • Prior to diagnosis, five dentists reported that the patient had anisocoria, migraine headaches, and low-to-moderate upper jaw pain that was refractory to conventional therapy.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Facial Pain / diagnosis. Maxillary Diseases / diagnosis. Maxillary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anisocoria / diagnosis. Denture Design. Denture, Partial, Temporary. Diagnosis, Differential. Female. Humans. Migraine Disorders / diagnosis. Palatal Obturators. Prosthesis Design. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776413.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W: Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys; 2009 Feb 1;73(2):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor histologic type was adenocarcinoma in 54, squamous cell carcinoma in 17, esthesioneuroblastoma in 9, and adenoid cystic carcinoma in 4.
  • The 5-year local control, overall survival, disease-specific survival, disease-free survival, and freedom from distant metastasis rate was 70.7%, 58.5%, 67%, 59.3%, and 82.2%, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Hospitals, University. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755554.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Carlos-Bregni R, Vidaurre EC, Carolina Netto A, León JE, Almeida OP: Primary intraosseous adenoid cystic carcinoma of the mandible: histopathological and immunohistochemical analysis. Pathol Oncol Res; 2009 Dec;15(4):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraosseous adenoid cystic carcinoma of the mandible: histopathological and immunohistochemical analysis.
  • Primary intraosseous salivary gland tumors of the mandible are rare, with mucopidermoid carcinoma being the most frequent, followed by adenoid cystic carcinoma (ACC).
  • We present a case of a central ACC involving the mandible of a 46-year-old man.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2009 Jul;31(7):975-80 [19189335.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Mar;65(3):316-26 [2451197.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug;104(2):e21-6 [17142071.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):495-500 [16997117.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Mar;50(3):229-36 [1311758.001]
  • [Cites] Ann Diagn Pathol. 2001 Dec;5(6):330-4 [11745070.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):83-7 [15943036.001]
  • [Cites] Am J Dermatopathol. 1991 Apr;13(2):162-8 [1709341.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1390-7 [7509254.001]
  • [Cites] J Oral Pathol Med. 2008 May;37(5):309-18 [18248354.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(4):240-4 [7690238.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):733-9 [16513325.001]
  • [Cites] Oral Dis. 2005 Mar;11(2):109-12 [15752085.001]
  • [Cites] J Oral Maxillofac Surg. 2008 Nov;66(11):2247-53 [18940488.001]
  • [Cites] J Oral Maxillofac Surg. 2008 Dec;66(12):2609-15 [19022143.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1955 May;8(5):546-55 [14370786.001]
  • [Cites] J Endod. 2000 Dec;26(12):760-3 [11471650.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):304-8 [16504862.001]
  • [Cites] Ann Diagn Pathol. 2000 Dec;4(6):347-53 [11149964.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 May;95(5):586-93 [12738950.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):995-1000 [17079351.001]
  • (PMID = 19381875.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Vimentin; 0 / beta Catenin; 68238-35-7 / Keratins
  •  go-up   go-down


74. Hao L, Xiao-lin N, Qi C, Yi-ping Y, Jia-quan L, Yan-ning L: Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int J Oral Sci; 2010 Mar;2(1):35-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma.
  • AIM: To detect the expression of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in salivary adenoid cystic carcinoma (SACC) tissues, as well as to determine the correlation between growth factor expression and prognosis in SACC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Nerve Growth Factor / analysis. Salivary Gland Neoplasms / pathology. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690417.001).
  • [ISSN] 1674-2818
  • [Journal-full-title] International journal of oral science
  • [ISO-abbreviation] Int J Oral Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9061-61-4 / Nerve Growth Factor
  • [Other-IDs] NLM/ PMC3475596
  •  go-up   go-down


75. Bhattacharyya N, Fried MP: Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol; 2005 Jan-Feb;26(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of survival in parotid gland carcinoma: a population-based study.
  • PURPOSE: To determine survival and factors influencing survival for parotid gland cancer.
  • Subset analysis was conducted for mucoepidermoid carcinoma according to grade.
  • Mean tumor size at diagnosis was 2.7 cm; 38.0% of patients had extraglandular extension of the tumor, 26.8% of patients had positive nodal disease, and 59.4% of patients received radiation therapy.
  • Tumor histology did predict survival, with squamous cell carcinoma and acinar cell carcinoma exhibiting the poorest and best survivals, respectively.
  • Increasing tumor grade, nodal disease, and extraglandular extension carried particularly high hazards ratios.
  • Patients with multiple poor prognostic features such as extraglandular extension, aggressive tumor histologies, and nodal disease will exhibit poorer survivals and may be candidates for more aggressive treatment protocols.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Parotid Neoplasms / mortality
  • [MeSH-minor] Age Factors. Carcinoma, Acinar Cell / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / mortality. Female. Humans. Male. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. SEER Program. Sex Factors. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635580.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Jeong HS, Son YI, Baek CH: The pattern of lymphatic metastasis of malignant tumors in the periorbital area. Am J Otolaryngol; 2006 Jan-Feb;27(1):5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnoses were 3 squamous cell carcinomas, 2 adenoid cystic carcinomas, 2 sebaceous carcinomas, and 1 basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Korea. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360815.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Miyamoto J, Tatsuzawa K, Owada K, Kawabe T, Sasajima H, Mineura K: Usefulness and limitations of fluorine-18-fluorodeoxyglucose positron emission tomography for the detection of malignancy of orbital tumors. Neurol Med Chir (Tokyo); 2008;48(11):495-9; discussion 499
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination identified 7 lesions as malignant: anaplastic astrocytoma of the optic nerve in 1 patient, which recurred as glioblastoma of the optic nerve, malignant lymphoma of mucosa-associated lymphoid tissue type in 1 patient, malignant melanoma in 1 patient, adenoid cystic carcinoma in 2 patients, and adenocarcinoma (unknown origin) in 1 patient.
  • [18F]FDG PET can determine the malignancy of orbital tumors, but cannot distinguish malignant tumor from inflammatory disease such as pseudotumor.
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adolescent. Adult. Aged. Astrocytoma / radionuclide imaging. Carcinoma, Adenoid Cystic / radionuclide imaging. Diagnosis, Differential. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Glioblastoma / radionuclide imaging. Hemangioma, Cavernous, Central Nervous System / radionuclide imaging. Humans. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Male. Melanoma / radionuclide imaging. Middle Aged. Neurilemmoma / radionuclide imaging. Orbital Pseudotumor / radionuclide imaging. Radiopharmaceuticals. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029776.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


79. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


80. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Murray BW, Lyons LC, Mancino AT, Huerta S: A report of laryngeal adenocystic carcinoma metastatic to the spleen and the role of splenectomy in the management of metastatic disease: a case report. J Med Case Rep; 2010;4:207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A report of laryngeal adenocystic carcinoma metastatic to the spleen and the role of splenectomy in the management of metastatic disease: a case report.
  • INTRODUCTION: Adenoid cystic carcinoma (ACC) of the larynx is a rare malignancy characterized by an indolent course and late pulmonary metastases.
  • In the present report, we discuss a patient with adenoid cystic carcinoma of the larynx metastatic to the spleen.
  • We review the clinical presentation and course of adenoid cystic carcinoma, as well as the role of splenectomy for metastases.
  • CASE PRESENTATION: We present a case of laryngeal adenoid cystic carcinoma in a 26-year-old Caucasian man treated with total laryngectomy and ionizing radiation.
  • Our patient subsequently presented with a symptomatic splenic lesion consistent with metastatic disease, for which he underwent laparoscopic splenectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Otolaryngol. 1975;4(2):290-2 [166744.001]
  • [Cites] Arch Otolaryngol. 1974 Aug;100(2):81-90 [4367208.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1974 Jul;82(4):499-506 [4854372.001]
  • [Cites] J Otolaryngol. 1983 Jun;12(3):151-4 [6308279.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1983;45(5):245-56 [6312389.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1983 Sep-Oct;92(5 Pt 1):491-5 [6312865.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):244-7 [7622112.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):407-10 [10053114.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] Am Surg. 2000 Sep;66(9):837-40 [10993611.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):306-10 [11404506.001]
  • [Cites] Head Neck. 2002 Aug;24(8):779-83 [12203804.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):38-43 [12831922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9 [16904520.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):965-9 [17550328.001]
  • [Cites] Head Neck. 2008 Jul;30(7):919-24 [18302260.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 May;33(5):790-3 [18343149.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 May;135(5):667-71 [18936972.001]
  • [Cites] South Med J. 2009 Jul;102(7):733-5 [19487993.001]
  • (PMID = 20604942.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2908633
  •  go-up   go-down


82. Shi H, Wang J, Dong FS, Wang X, Li HX: [Relationship between proteoglycans and proliferation of human salivary adencid cystic carcinoma]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Jan;45(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between proteoglycans and proliferation of human salivary adencid cystic carcinoma].
  • OBJECTIVE: To investigate the effect of down-regulated proteoglycans on the proliferation of human salivary adenoid cystic carcinoma (SACC).
  • Adenoid cystic carcinoma cells with high metastatic tendency (ACC-M) were transfected by shRNA-WJ3.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cell Proliferation. Pentosyltransferases / metabolism. Proteoglycans / metabolism. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20368035.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.26 / UDP xylose-protein xylosyltransferase
  •  go-up   go-down


83. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM: Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1070-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Between 1964 and 2000, 273 patients with tumors of the nasopharynx, paranasal sinuses, nasal cavity, and hard palate adenoid cystic carcinomas were treated with curative intent and had radiation fields that included the optic nerves and/or chiasm.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990010.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


84. Xie W, Li X, Ren G, Guo W: Expression and importance of inhibitor of DNA binding helix-loop-helix protein in salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg; 2010 Sep;48(6):434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and importance of inhibitor of DNA binding helix-loop-helix protein in salivary adenoid cystic carcinoma.
  • Studies have reported that Id-1 (inhibitor of DNA binding, or differentiation 1) protein, helix-loop-helix (HLH) transcription factor, has important roles in the development of several carcinomas.
  • However, the role of Id-1 protein in salivary adenoid cystic carcinoma (ACC) is not clear.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Inhibitor of Differentiation Protein 1 / biosynthesis. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19766362.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Inhibitor of Differentiation Protein 1
  •  go-up   go-down


85. Zhang Y, Liu J, Xue F, Li J: p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jul;100(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83.
  • OBJECTIVE: This study aimed to determine the growth inhibitory effects of transfecting the wild-type p16 gene into human salivary adenoid cystic carcinoma (SACC) cells in vitro.
  • METHODS: p16 cDNA was cloned into pDOR-neo plasmid by recombination technique, and the human eukaryotic expression vector, pDOR-p16 , was constructed.
  • CONCLUSION: The study confirmed the reversal effect of wild-type p16 on malignant phenotype of the salivary adenoid cystic carcinoma and provides valuable data for further clinical trial of gene therapy with p16.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Genes, p16 / physiology. Genetic Therapy. Salivary Gland Neoplasms / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953919.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 9007-49-2 / DNA
  •  go-up   go-down


86. Soysal HG: Orbital exenteration: a 10-year experience of a general oncology hospital. Orbit; 2010 Jun;29(3):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital exenteration: a 10-year experience of a general oncology hospital.
  • The age, sex, the location of tumour, the duration of symptoms, histopathological diagnosis, and previous recurrences were noted.
  • Seven different types of histopathology were encountered: squamous cell carcinoma (31 cases), basal cell carcinoma (26 cases), malignant melanoma (5 cases), sebaceous cell carcinoma (2 cases), rhabdomyosarcoma (2 cases), mucoepidermoid carcinoma (1 case) and adenoid cystic carcinoma (1 case).
  • CONCLUSIONS: Large proportion of the patients that underwent exenteration had a history of previous unsuccessful treatment and a long duration of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497078.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Zhang Q, Yang L, Yang AK, Guo ZM: [Clinical study on 88 cases of adenoid cystic carcinoma in nasal cavity and paranasal sinuses]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Apr;44(4):311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on 88 cases of adenoid cystic carcinoma in nasal cavity and paranasal sinuses].
  • OBJECTIVE: To study the clinical characters, diagnosis, management and prognosis of patients with adenoid cystic carcinoma in nasal cavity and paranasal sinuses.
  • METHODS: The data were analyzed retrospectively for 88 patients with adenoid cystic carcinoma in nasal cavity and paranasal sinuses, to evaluate the clinical characters, diagnostic and therapeutical aspects and the contribution of every factor influencing the survival.
  • CONCLUSIONS: Advanced adenoid cystic carcinoma should be treated by combined surgical operation and radiotherapy.
  • Stage and treatment approach are the independent factors affecting the prognoses of patients with adenoid cystic carcinoma in nasal cavity and paranasal sinuses.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Nose Neoplasms. Paranasal Sinus Neoplasms

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558839.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Yurut-Caloglu V, Caloglu M, Ozyilmaz F, Saynak M, Cosar-Alas R, Karagol H, Bayir-Angin G, Uzal C: Lung, bone, skeletal muscles and cutaneous metastases from adenoid cystic carcinoma of the parotid gland: a case report and review of the literature. Med Oncol; 2007;24(4):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung, bone, skeletal muscles and cutaneous metastases from adenoid cystic carcinoma of the parotid gland: a case report and review of the literature.
  • Adenoid cystic carcinoma is the second most common malignancy of the major and minor salivary glands after mucoepidemoid carcinoma.
  • Skeletal muscle and cutaneous metastases from adenoid cystic carcinoma of the parotid gland are extremely rare.
  • In this case, a 40-year-old man with lung and bone metastases followed by skeletal muscle and cutaneous metastases from adenoid cystic carcinoma of the right parotid gland is presented.
  • [MeSH-major] Bone Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Lung Neoplasms / diagnosis. Muscle Neoplasms / diagnosis. Parotid Neoplasms / pathology. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Oncol. 1984;31(1):57-67 [6545428.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):1000-4 [16165713.001]
  • [Cites] BMC Cancer. 2004 Jul 30;4:41 [15285782.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):217-23 [15028021.001]
  • [Cites] Acta Otolaryngol. 2005 Jun;125(6):678-82 [16076722.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):589-90 [6295610.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):593-7 [15308260.001]
  • [Cites] J Am Acad Dermatol. 1995 Oct;33(4):649-57 [7545706.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):290-7 [11479041.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1530-4 [2434211.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):855-8 [16086994.001]
  • [Cites] Virchows Arch. 1997 Mar;430(3):227-32 [9099980.001]
  • [Cites] J Am Acad Dermatol. 1999 Apr;40(4):640-2 [10188691.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52 [10037280.001]
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] J Laryngol Otol. 2001 Aug;115(8):673-5 [11535157.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):501-2 [12056698.001]
  • [Cites] Surg Neurol. 1998 Nov;50(5):475-9 [9842876.001]
  • [Cites] Eur J Cancer Care (Engl). 2005 Jul;14(3):267-71 [15952972.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):775-9 [12828706.001]
  • (PMID = 17917100.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


89. Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H: Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer; 2009 Feb 24;100(4):623-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.
  • Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy.
  • Recently, we identified two EGFR mutations in a cohort of 25 salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21 by allele-specific PCR.
  • No additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an adenoid cystic carcinoma have been detected.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Oral Oncol. 2009 Jul;45(7):574-8 [18804410.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8418-24 [16322304.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1817-24 [17888036.001]
  • [Cites] HNO. 2008 Feb;56(2):231-8 [18214402.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):907-14 [18283321.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2442-9 [18458038.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):30-4 [18192072.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):90-2 [18542074.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1168-75 [18587327.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • (PMID = 19174819.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2653741
  •  go-up   go-down


90. Völker HU, Scheich M, Berndt A, Haubitz I, Metzger A, Müller-Hermelink HK, Kämmerer U, Schmidt M: Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses. Diagn Pathol; 2009;4:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.
  • BACKGROUND: Adenoid cystic carcinomas are rare tumors with an indolent clinical course, but frequent local relapses.
  • CONCLUSION: Adenoid cystic carcinomas positive for p-AKT show a higher relapse risk.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6 [17639446.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):645-52 [18402531.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):33-6 [16757202.001]
  • [Cites] Oral Oncol. 2006 Sep;42(8):759-69 [16757203.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1681-8 [16275989.001]
  • [Cites] Clin Lab. 2005;51(5-6):257-73 [15991799.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2599-601 [10470201.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):345-54 [9387095.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):512-20 [4371368.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):294-9 [15468132.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):127-32 [15167050.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1015-24 [12569601.001]
  • [Cites] Br J Plast Surg. 2001 Sep;54(6):476-80 [11513507.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):928-34 [11309343.001]
  • [Cites] Cancer Lett. 2000 Sep 29;158(1):103-8 [10940516.001]
  • [Cites] Oral Oncol. 2009 Feb;45(2):156-63 [18620900.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):393-412 [18721898.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Jun;34(3):293-300 [18686341.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8 [18394773.001]
  • [Cites] Am J Clin Pathol. 2008 Jul;130(1):50-7 [18550470.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):215-20 [17192790.001]
  • (PMID = 19545368.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2704178
  •  go-up   go-down


91. Qi ZZ, Shang DH, Qu CF, Sun CF: [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma]. Shanghai Kou Qiang Yi Xue; 2007 Jun;16(3):243-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma].
  • PURPOSE: To study the expression and clinical significance of M-phase promoting factor (MPF) in salivary adenoid cystic carcinoma (SACC).
  • METHODS: The expression of MPF was investigated in 40 salivary adenoid cystic carcinomas and 40 normal salivary tissues by immunohistochemistry.
  • RESULTS: The expression of MPF was significantly higher in salivary adenoid cystic carcinoma than in normal salivary tissues(P<0.05).
  • There was significant correlation between the level of MPF expression and pathological type(P<0.05).
  • CONCLUSIONS: MPF highly expressed in salivary adenoid cystic carcinoma, salivary adenoid cystic carcinoma correlated with the expression of MPF and the abnormal activation of MPF was one of the factors for the proliferation of salivary adenoid cystic carcinoma.
  • Metastasis in salivary adenoid cystic carcinoma correlated with the expression of MPF.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Maturation-Promoting Factor / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660907.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.22 / Maturation-Promoting Factor
  •  go-up   go-down


92. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human kallikrein 8 protein (KLK8) is expressed in many normal tissues including esophagus, skin, testis, tonsil, kidney, breast, and salivary gland, and is found in biological fluids including breast milk, amniotic fluid, seminal fluid and serum.
  • It has also been shown to be a biomarker and prognostic factor for breast cancer.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Kallikreins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands, Minor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Humans. Immunoenzyme Techniques

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


93. Gil Z, Rein A, Brader P, Li S, Shah JP, Fong Y, Wong RJ: Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin Cancer Res; 2007 Nov 1;13(21):6479-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The invasion of cancer cells along nerves is an ominous pathologic finding associated with poor outcomes for a variety of tumors, including pancreatic and head and neck carcinomas.
  • Cancer progression within nerves and surgical resection of infiltrated nerves result in a permanent loss of neural function, potentially causing cosmetic and functional morbidity.
  • EXPERIMENTAL DESIGN AND RESULTS: NV1023 injection into the sciatic nerves of nude mice had no toxic effect on nerve function, whereas similar doses of wild-type HSV-1 (F' strain) caused complete nerve paralysis within 4 days and 100% mortality at day 6.
  • NV1023 showed effective cytotoxicity in vitro on three neurotrophic human carcinoma cell lines, including pancreatic (MiaPaCa2), squamous cell (QLL2), and adenoid cystic (ACC3) carcinomas.
  • A model of neural invasion was established by implanting human carcinoma cells in the sciatic nerves of nude mice.
  • These findings hold significant clinical implications for patients with cancer neural invasion.
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Progression. Gene Transfer Techniques. Humans. Mice. Mice, Nude. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction. Sciatic Nerve / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975160.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol; 2006 Sep;42(8):759-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
  • Adenoid cystic carcinoma (ACC) accounts for about 1% of all head and neck malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Salivary Gland Neoplasms / drug therapy


95. Bonanno A, Esmaeli B, Fingeret MC, Nelson DV, Weber RS: Social challenges of cancer patients with orbitofacial disfigurement. Ophthal Plast Reconstr Surg; 2010 Jan-Feb;26(1):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Social challenges of cancer patients with orbitofacial disfigurement.
  • The authors studied the interaction of cancer patients who had undergone orbital exenteration with family members and friends (primary groups) and with acquaintances and strangers (secondary groups) in small and large groups.
  • METHODS: In-depth telephone interviews were conducted with 12 patients treated at a cancer center (7 men and 5 women aged 51-81 years) and 12 family members (8 spouses and 4 children or siblings).
  • Three patients had adenoid cystic carcinoma of lacrimal gland, 3 had squamous cell carcinoma of conjunctiva/eyelid, and 1 each had conjunctival melanoma, eyelid sebaceous gland carcinoma, transitional cell carcinoma of lacrimal sac, adenocarcinoma of orbit, neuroendocrine carcinoma of orbit, and basal cell carcinoma of eyelid.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090478.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Li Z, Cen Y, Yang K: [Modified transcranial approach to resect tumor around the anterior skull base and double tissue flap to reconstruct the anterior skull base]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Sep;20(9):896-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In November 2004, a 49-years-old male patient with intracranial recrudescent adenoid cystic carcinoma in the anterior cranial fossa was treated using modified transcranial approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036975.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Bi YW, Chen RJ: [Clinical and pathological analysis of 151 cases of tumors in lacrimal fossa]. Zhonghua Yan Ke Za Zhi; 2005 Oct;41(10):877-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 69 cases of benign lacrimal epithelial tumors, pleomorphic adenoma was the most common tumor (63 cases, 41.7%), followed by myoepithelioma (3 cases, 1.2%), lacrimal duct cyst (2 cases, 1.3%).
  • In 34 cases of malignant lacrimal epithelial tumors, adenoid cystic carcinoma was the most common tumor (15 cases, 9.9%), followed by pleomorphic adenocarcinoma (14 cases, 9.3%), adenocarcinoma (4 cases, 2.6%).
  • The treatment of pleomorphic adenoma and the diagnosis of MALT lymphoma are the most difficult tasks in present clinical work.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Orbital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271170.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Korkontzelos I, Fragkoulidis M, Stavroulis A, Apostolikas N, Terzakis E: Adenoid cystic carcinoma of the Bartholin's gland in a young patient: eight-year follow-up. Eur J Gynaecol Oncol; 2009;30(6):686-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the Bartholin's gland in a young patient: eight-year follow-up.
  • Adenoid cystic carcinoma (ACC) of the Bartholin's gland is one of the rarest neoplasms of the female genital tract.
  • We report a case of a 36-year-old woman who presented at our hospital after excision of the right Bartholin gland elsewhere which proved to be ACC.
  • Our patient underwent surgical treatment only (hemivulvectomy and lymph node dissection) without radiotherapy and is free of disease eight years after.
  • [MeSH-major] Bartholin's Glands / pathology. Carcinoma, Adenoid Cystic / pathology. Vulvar Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099506.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


99. Al-Khateeb TH, Ababneh KT: Salivary tumors in north Jordanians: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May;103(5):e53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were analyzed for age of patient, sex of patient, tumor site, and tumor type.
  • The most frequent benign and malignant neoplasms found were pleomorphic adenoma (54%) and adenoid cystic carcinoma (13%), respectively.
  • Although most of major gland tumors were adenomas, carcinomas of the minor glands were only slightly less frequent than adenomas.
  • The most frequent malignant parotid tumors were adenoid cystic carcinoma and mucoepidermoid carcinoma.
  • The most frequent minor salivary gland malignant tumors were palatal adenoid cystic carcinoma.
  • CONCLUSION: North Jordanians with salivary gland tumors were found to have similar characteristics with patients of other countries with regard to tumor type, tumor site distribution, and age and sex of patients.
  • [MeSH-major] Adenoma, Pleomorphic / epidemiology. Carcinoma, Adenoid Cystic / epidemiology. Salivary Gland Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368055.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • The histopathological diagnosis is difficult, mainly because this tumour is exceptional.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down






Advertisement